Jeffrey M. Holzbeierlein, MD, presented “Blue Light Cystoscopy: How Does It Fit into the Non-Muscle Invasive Bladder Cancer Guidelines?” during the 40th Annual Ralph E. Hopkins Urology Seminar on February 5th, 2020 in Jackson Hole, Wyoming.
How to cite: Holzbeierlein, Jeffrey M. “Blue Light Cystoscopy: How Does It Fit into the Non-Muscle Invasive Bladder Cancer Guidelines?” February 5th, 2020. Accessed Jul 2024. https://grandroundsinurology.com/blue-light-cystoscopy-how-does-it-fit-into-the-non-muscle-invasive-bladder-cancer-guidelines/
Blue Light Cystoscopy: How Does It Fit into the Non-Muscle Invasive Bladder Cancer Guidelines? – Summary:
Jeffrey M. Holzbeierlein, MD, Director of the Division of Urologic Oncology at the University of Kansas Hospital and Director of Clinical Research for the Urology Department at KUMC, discusses how using Blue Light Cystoscopy (BLC), an enhanced imaging technique that creates a visible contrast between normal urothelium and cancer cells, can improve detection of non-muscle invasive bladder cancer (NMIBC). The AUA, EAU, and NCCN recommend BLC for use in many bladder cancer patients, especially those with positive cytology but negative white light cystoscopy (WLC), but many practitioners eschew BLC due to the expensive equipment required. Dr. Holzbeierlein suggests that the benefits may outweigh the costs, citing multiple studies that have reported increased rates of detection and lower rates of recurrence of NMIBC with BLC vs. WLC, although he acknowledges that researchers have yet to prove that the use of BLC improves progression. Dr. Holzbeierlein concludes by discussing BLC’s particular utility in detecting carcinoma in situ (CIS), which he believes leads to improved resection of CIS and thus better patient response to bacillus Calmette-Guérin.
About The 40th Annual Ralph E. Hopkins Urology Seminar:
The Ralph E. Hopkins Urology Seminar is a multi-day meeting focused on training urologists in the latest in assessing, diagnosing, and treating urologic conditions in the clinical setting. Updates are provided on urologic cancers, stone disease, urologic reconstruction, female urology, infertility, emerging surgical techniques, and general urology. Dr. Holzbeierlein presented this lecture during the 40th iteration of the meeting on February 5th, 2020 in Jackson Hole, Wyoming.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Jeffrey M. Holzbeierlein, MD, is Director of the Division of Urologic Oncology at the University of Kansas Hospital and Director of Clinical Research for the Urology Department at the University of Kansas Medical Center. He attended Vanderbilt University and then completed his medical degree at the University of Oklahoma before returning to Vanderbilt to complete his residency in urology. After completion of his residency, Dr. Holzbeierlein spent 2 years completing his Fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center before joining the faculty at the University of Kansas Medical Center in Kansas City, Kansas, in 2002. Dr. Holzbeierlein’s research interests are focused on the androgen receptor and heat shock protein 90. He continues to have an active basic science laboratory whose work has been supported by a Department of Defense New Investigator award on which he was the Principal Investigator and by 2 R01 grants on which he is a co-investigator. His clinical research has focused on bladder cancer, including identification of clinical factors that predict response to chemotherapy and immunonutrition for patients undergoing cystectomy. He has numerous peer-reviewed publications both in basic science and clinical research. Dr. Holzbeierlein has been very involved in the South Central Section, the Society for Urologic Oncology, and the American Urological Association. He is credited with founding the Young Urologic Oncologists section of the Society of Urologic Oncology and served as its President for 2 years. He served on the Fellowship Committee of the SUO for 5 years and is the past Chair of the Fellowship Committee, and currently serves on the Executive Board for the SUO. He was awarded the Distinguished Contribution medal from the SUO in 2013 for his work on the Fellowship Committee. Within the AUA, Dr. Holzbeierlein serves on the Practice Guidelines Committee and the Public Media Committee. He was previously a member of the Section Secretaries Membership Council and was on the American Board of Urology Examination Committee from 2010-2014. In addition, Dr. Holzbeierlein served as the Kansas State Representative to the Board of the South Central Section from 2008 to 2010 and completed the AUA’s Leadership course in 2008.
